Skip to content
10-Q

Quarterly Report

PURE Bioscience, Inc. PURE

0001493152-25-010576

← back to feed
Filed
Mar 17, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Mar 17, 2025 111.86M sh
Current Liabilities Q2 2025 · Jan 31, 2025 $866K
Current Liabilities Q2 2025 · Jul 31, 2024 $733K
Total Liabilities Q2 2025 · Jan 31, 2025 $4.84M
Total Liabilities Q2 2025 · Jul 31, 2024 $3.68M
Current Assets Q2 2025 · Jan 31, 2025 $562K
Current Assets Q2 2025 · Jul 31, 2024 $805K
Total Assets Q2 2025 · Jan 31, 2025 $574K
Total Assets Q2 2025 · Jul 31, 2024 $818K
Cash And Equivalents Q2 2025 · Jul 31, 2024 $349K
Cash And Equivalents Q2 2025 · Jan 31, 2024 $557K
Shares Diluted Q2 2025 · Jan 31, 2024 111.86M sh
Shares Diluted Q2 2025 · Jan 31, 2024 111.86M sh
Operating Cash Flow Q2 2025 · Jan 31, 2024 −$1.32M
Stockholders Equity Q2 2025 · Jan 31, 2024 −$1.32M
Stockholders Equity Q2 2025 · Oct 31, 2023 −$383K
Stockholders Equity Q2 2025 · Jul 31, 2023 $272K
Eps Diluted restated Q2 2025 · Jan 31, 2024 −$0.01
Eps Diluted restated Q2 2025 · Jan 31, 2024 −$0.02
Eps Basic restated Q2 2025 · Jan 31, 2024 −$0.01
Eps Basic restated Q2 2025 · Jan 31, 2024 −$0.02
Sga Expense Q2 2025 · Jan 31, 2024 $1.07M
Sga Expense Q2 2025 · Jan 31, 2024 $2.14M
Rd Expense Q2 2025 · Jan 31, 2024 $76K
Rd Expense Q2 2025 · Jan 31, 2024 $156K
Net Income Q2 2025 · Jan 31, 2024 −$1M
Net Income Q2 2025 · Jan 31, 2024 −$1.74M
Operating Income Q2 2025 · Jan 31, 2024 −$964K
Operating Income Q2 2025 · Jan 31, 2024 −$1.68M
Gross Profit Q2 2025 · Jan 31, 2024 $177K
Gross Profit Q2 2025 · Jan 31, 2024 $619K
Cost Of Revenue Q2 2025 · Jan 31, 2024 $149K
Cost Of Revenue Q2 2025 · Jan 31, 2024 $429K
Revenue Q2 2025 · Jan 31, 2024 $326K
Revenue Q2 2025 · Jan 31, 2024 $1.05M